IMUGENE LIMITED (ASX:IMU) - Ann: Investor Webinar - Final HER-Vaxx Overall Survival Results, page-19 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by SENARIS ↑

From FDA website:

Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions.
Determining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one. AIDS, Alzheimer’s, heart failure and cancer are obvious examples of serious conditions. However, diseases such as epilepsy, depression and diabetes are also considered to be serious conditions.
Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.
Any drug being developed to treat or prevent a condition with no current therapy obviously is directed at an unmet need. If there are available therapies, a fast track drug must show some advantage over available therapy, such as:

Showing superior effectiveness, effect on serious outcomes or improved effect on serious outcomes

Avoiding serious side effects of an available therapy

Improving the diagnosis of a serious condition where early diagnosis results in an improved outcome

Decreasing a clinical significant toxicity of an available therapy that is common and causes discontinuation of treatment

Ability to address emerging or anticipated public health need

A drug that receives Fast Track designation is eligible for some or all of the following:

More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval

More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers

Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met

Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA

Fast Track designation must be requested by the drug company. The request can be initiated at any time during the drug development process. FDA will review the request and make a decision within sixty days based on whether the drug fills an unmet medical need in a serious condition.
Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.

Expand

Another bio pharma got FDA fast track designation for their Osteoarthritis treatment, but they are in Phase 3 trials.
Just looked at this link and it does say sometimes Phase 2 can apply for NDA
https://www.google.com/amp/s/amp.ca...u-need-to-know/phases-of-clinical-trials.html

No.	Vol.	Price($)
7	1082545	5.5¢

No.

Vol.

Price($)

1082545

5.5¢

Price($)	Vol.	No.
5.7¢	603058	6

Price($)

Vol.

No.

5.7¢

603058

No.	Vol.	Price($)
4	341818	0.055
9	509187	0.054
14	1776123	0.053
22	1646348	0.052
16	4794350	0.051

No.

Vol.

Price($)

341818

0.055

509187

0.054

1776123

0.053

1646348

0.052

4794350

0.051

Price($)	Vol.	No.
0.057	603058	6
0.058	1006279	6
0.059	21714	1
0.060	1512398	12
0.061	1091000	7

Price($)

Vol.

No.

0.057

603058

0.058

1006279

0.059

21714

0.060

1512398

0.061

1091000

(20min delay)
Last 5.7¢		Change 0.001(1.79%)		Mkt cap ! $418.9M

Open	High	Low	Value	Volume
5.6¢	5.7¢	5.4¢	$461.9K	8.347M

Ann: Investor Webinar - Final HER-Vaxx Overall Survival Results, page-19

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

Imricor raises $35M to pursue growth and expansion into Australia and NZ

AI stocks: What to expect in 2024-25

Talking Australia's very competitive property landscape: Realty Talks

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Metalicity looking for offers on Admiral Bay zinc project

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Webinar - Final HER-Vaxx Overall Survival Results, page-19

Top Stories

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

Imricor raises $35M to pursue growth and expansion into Australia and NZ

AI stocks: What to expect in 2024-25

Talking Australia's very competitive property landscape: Realty Talks

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Metalicity looking for offers on Admiral Bay zinc project

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News